Cancer diagnosis and treatment redefine normality, with chronic conditions like follicular lymphoma posing ongoing challenges ...

FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data ...

Follicular lymphoma tends to grow slowly and often doesn’t cause symptoms in its early stages. Swollen lymph nodes — typically in your armpits, neck, groin, and thighs — are usually the first symptom.

Early rituximab monotherapy led to a substantial delay in the need for new treatment in patients with advanced stage, asymptomatic, low tumour burden follicular lymphoma. After a median follow-up ...

Although follicular lymphoma is characterized by long natural history and frequent relapses, data on the number of patients receiving subsequent therapy lines are scarce. To perform reliable health ...

Incyte’s previously disclosed phase 3 win in relapsed or refractory follicular lymphoma (R/R FL) sent the company racing to file an expansion bid for its Monjuvi (tafasitamab) by year-end. Now, a ...

The US Food and Drug Administration has approved tafasitamab (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory (r/r) follicular lymphoma (FL).

(a) The smear is composed of blood only (smear, Diff-Quik stain). (b) The smear shows foamy macrophages and degenerated cyst fluid, with no follicular cells (smear, Diff-Quik stain). (c) Scant ...

Covers low tumor burden “watch-and-wait” setting, an unmet medical needRegistrational Phase 3 watch-and-wait to start in 2026EO2463 has broad potential to treat hemato-oncology indications Paris, ...